Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Larissa Camejo

Ophthalmology Palm Beach Gardens, FL Medical Doctor

NPI 1447286190 CMS profile 292160

11211 Prosperity Farms Rd Ste D127, Palm Beach Gardens, FL 33410

Open in the dashboard

General payments

$244,334

479 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Larissa Camejo of Palm Beach Gardens, FL is reported in the CMS Open Payments database as having received $244,334 across 479 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54,565 117
2024 General $33,994 109
2023 General $34,991 62
2022 General $40,917 76
2021 General $18,612 35
2020 General $21,352 25
2019 General $39,902 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Larissa Camejo
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Larissa Camejo were reported at $54,565. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Larissa Camejo Ophthalmology median Middle half National median
2019 $39,902 $258 $104–$655 $163
2020 $21,352 $126 $45–$321 $114
2021 $18,612 $205 $76–$534 $132
2022 $40,917 $266 $100–$678 $149
2023 $34,991 $308 $117–$745 $160
2024 $33,994 $340 $127–$846 $164
2025 $54,565 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $69,703 110 payments
  2. Aerie Pharmaceuticals, Inc. $64,171 46 payments
  3. Sight Sciences, Inc. $24,268 43 payments
  4. Nova Eye, Inc. $22,090 5 payments
  5. Glaukos Corporation $13,964 48 payments
  6. New World Medical,Inc. $12,516 26 payments
  7. Alcon Vision LLC $10,703 43 payments
  8. Allergan Inc. $10,522 21 payments
  9. Johnson & Johnson Surgical Vision, Inc. $6,168 16 payments
  10. Ellex, Inc $3,063 2 payments
  11. Other $7,167 119 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $105,569 40 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $87,023 37 payments
  3. Travel and Lodging $19,245 24 payments
  4. Food and Beverage $18,426 361 payments
  5. Honoraria $11,750 6 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,000 1 payment
  7. Education $222 7 payments
  8. Entertainment $59 1 payment
  9. Gift $39 2 payments
Products named General payments · program years 2019–2025
  1. rocklatan Glaucoma $39,621 28 payments
  2. rhopressa Glaucoma $39,502 24 payments
  3. DURYSTA Eye Care $36,617 62 payments
  4. Rocklatan Glaucoma $31,511 30 payments
  5. Rhopressa Glaucoma $19,433 18 payments
  6. XEN GLAUCOMA TREATMENT SYSTEM Glaucoma $17,820 15 payments
  7. XEN GLAUCOMA TREATMENT SYSTEM Eye Care $15,138 21 payments
  8. DURYSTA Glaucoma $11,693 34 payments
  9. Ahmed Glaucoma Valve $11,151 21 payments
  10. Kahook Dual Blade $11,151 21 payments
  11. Other $98,490 342 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

4,518

Median for Ophthalmology: 891

Drug cost

$638,743

Median for Ophthalmology: $68,233

Branded share of claims

44.2%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 120 $114,099
Xiidra Lifitegrast Brand 81 $77,340
Rocklatan Netarsudil Mesylat/Latanoprost Brand 151 $65,389
Lumigan Bimatoprost Brand 146 $60,465
Vyzulta Latanoprostene Bunod Brand 146 $53,019
Rhopressa Netarsudil Mesylate Brand 134 $49,517
Combigan Brimonidine Tartrate/Timolol Brand 145 $45,880
Alphagan P Brimonidine Tartrate Brand 111 $28,552
Ilevro Nepafenac Brand 60 $24,174
Prednisolone Acetate Generic 301 $11,924

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$289,357

Of which drugs: $46,983

Medicare patients

303

Average age 78

Services billed

2,598

164 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 41%
Diabetes 33%
Ischemic heart disease 32%
Chronic kidney disease 28%
Atrial fibrillation 21%
Heart failure 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, bimatoprost, intracameral implant, 1 microgram J7351 Office 19 290 $46,983

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $5,050
$5,050 — 290
Rocklatan
  • Alcon Vision LLC $367
$367 151 —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $349
$349 — —
Simbrinza
  • Alcon Vision LLC $310
$310 54 —
Rhopressa
  • Alcon Vision LLC $310
$310 134 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

479 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record